Xin Kai has over 17 years of work experience in the field of immunotherapy and antibody research. Xin began their career in 2004 as a Ph.D. graduate student at Shandong University. In 2008, they became a joint Ph.D. student at Massachusetts General Hospital Cancer Center, Harvard Medical School, where they examined druggable signaling pathways in CLL patients and analyzed Sialic acid-binding immunoglobulin-type lectins (SIGLECs) family members’ expression of human PBMCs. In 2011, they became a Postdoctoral Research Fellow at the same institution and established a high-throughput gene-editing platform for somatic mutation studies and drug screening using CRISPR-Cas9 techniques. Xin then moved to the Ragon Institute of MGH, MIT and Harvard in 2015 as a Postdoctoral Research Fellow where they investigated O-acetylation of sialic acid in different immune cell populations and its regulation mechanisms of novel signal pathways in B cell tolerance, T-B cell collaboration and germinal center reaction of autoimmune disease. In 2017, they joined Compass Therapeutics LLC as a Scientist and identified and validated the lead molecules of monoclonal and bispecific antibodies with a focus on immune-oncology and autoimmunity targets. In 2019, they joined Luye Boston R&D as an Investigator & Manager, Translational Research, Cell Therapy and Antibody Research. Xin is currently the Director of immunotherapy, Discovery Biology at Hopewell Therapeutics Inc.
Xin Kai received a Bachelor's degree in Biologic Engineering from Qilu University of Technology from 2000 to 2004. Xin then went on to receive a Doctor of Philosophy (PhD) in Molecular and Cellular Immunology from Shandong University from 2004 to 2010.
November, 2021 - present
Assistant Professor, Fine & Performing Arts, GITAM School of Humanities & Social Sciences, Hyderabad Campus at GITAM Deemed University
SVP for Research at Penn State University
Chief Behavioral Science Officer And President Americas at Mind Gym
Dean, The College of Liberal Arts & Sciences, Natural Sciences at Arizona State University
President & Chief Science Officer at NULASTIN
Access the worlds's biggest network of public org charts
Learn more